DS
SRPT icon

David Shaw’s Sarepta Therapeutics SRPT Stock Holding History

David Shaw’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$180K Buy
+10,000
New +$189K ﹤0.01% 4573
2023
Q1 		– Sell
-10,000
Closed -$1.3M – 4838
2022
Q4 		$1.3M Hold
10,000
– – ﹤0.01% 3261
2022
Q3 		$1.1M Buy
+10,000
New +$1.01M ﹤0.01% 3520
2021
Q1 		– Sell
-10,000
Closed -$1.71M – 4458
2020
Q4 		$1.71M Hold
10,000
– – ﹤0.01% 2653
2020
Q3 		$1.4M Hold
10,000
– – ﹤0.01% 2633
2020
Q2 		$1.6M Sell
10,000
-2,000
-17% -$272K ﹤0.01% 2580
2020
Q1 		$1.17M Sell
12,000
-57,700
-83% -$6.6M ﹤0.01% 2613
2019
Q4 		$8.99M Sell
69,700
-1,400
-2% -$141K 0.01% 1271
2019
Q3 		$5.36M Buy
71,100
+10,000
+16% +$1.18M 0.01% 1596
2019
Q2 		$9.28M Sell
61,100
-20,000
-25% -$2.43M 0.01% 1173
2019
Q1 		$9.67M Sell
81,100
-65,000
-44% -$8.36M 0.01% 1128
2018
Q4 		$15.9M Buy
146,100
+10,000
+7% +$1.25M 0.02% 807
2018
Q3 		$22M Buy
136,100
+40,900
+43% +$5.59M 0.03% 735
2018
Q2 		$12.6M Buy
95,200
+35,200
+59% +$3.32M 0.02% 963
2018
Q1 		$4.45M Buy
60,000
+3,500
+6% +$233K 0.01% 1490
2017
Q4 		$3.14M Buy
56,500
+10,000
+22% +$530K ﹤0.01% 1815
2017
Q3 		$2.11M Hold
46,500
– – ﹤0.01% 1983
2017
Q2 		$1.57M Hold
46,500
– – ﹤0.01% 2131
2017
Q1 		$1.38M Sell
46,500
-20,000
-30% -$619K ﹤0.01% 2089
2016
Q4 		$1.82M Buy
66,500
+26,500
+66% +$1.06M ﹤0.01% 2059
2016
Q3 		$2.46M Hold
40,000
– – ﹤0.01% 1767
2016
Q2 		$763K Hold
40,000
– – ﹤0.01% 2571
2016
Q1 		$781K Buy
40,000
+30,000
+300% +$524K ﹤0.01% 2523
2015
Q4 		$386K Buy
+10,000
New +$324K ﹤0.01% 3239
2014
Q3 		– Sell
-12,500
Closed -$372K – 4374
2014
Q2 		$372K Buy
+12,500
New +$395K ﹤0.01% 3723

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

David Shaw's SRPT Position: Q2 2026 in Review

David Shaw sold out of Sarepta Therapeutics (SRPT) in Q2 2026, closing a stake of 474,986 shares — an estimated $8.98M sold.

David Shaw first reported a position in SRPT in Q2 2013 and held it in 47 quarters. The position peaked at $117M in Q1 2023. 320 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • David Shaw reported no remaining Sarepta Therapeutics position as of Q2 2026 after selling out during the quarter.
  • David Shaw sold 474,986 Sarepta Therapeutics shares in Q2 2026, an estimated $8.98M.
  • David Shaw first reported a position in Sarepta Therapeutics in Q2 2013 and held it in 47 quarters.
  • David Shaw's Sarepta Therapeutics position peaked at $117M in Q1 2023.
  • 320 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.